J&J’s Stelara arthritis drug is unaffordable, Colorado price board rules (NYSE:JNJ)

Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis drug could face a restrict on what well being plans in Colorado pay for the remedy after the state’s assessment board stated it was “unaffordable” for sufferers, Bloomberg Legislation reported. The Colorado Prescription Drug Affordability Board on Friday voted to designate Stelara, an injectable remedy for situations similar to average to extreme plaque psoriasis and Crohn’s illness, as too expensive. On account of the vote, the five-member board in a follow-up assembly will resolve whether or not to pursue an higher cost restrict (UPL) for the drug. The board decided that Stelara on common value $155,000 per Colorado affected person in 2022, Bloomberg Legislation reported. The board will meet subsequent on June 14.